Top Section/Ad
Top Section/Ad
Most recent
Pharmaceuticals and energy transition also ripe sectors for M&A
Munich-based company's deal is one of five launched this month
Big deal joins light supply in January
Bankers say deals are still being launched and believe international rivalry can be negotiated
More articles/Ad
More articles/Ad
More articles
-
AbbVie’s $63bn cash-and-shares bid for Allergan, a rival drug company, will add fuel to the pharmaceutical sector's M&A bonfire, with more jumbo deals expected before the year ends. A trip to the bond market for funds, including a large euro issue, is also likely, write Mike Turner and Alex Radford. -
Schuldschein borrowers, with the help of arranging banks, are for the first time offering different pricing ranges on issues of fixed and floating rates, as the market tries to find ways of dealing with the prolonged period of negative interest rates.
-
Korian cuts into loan margin with A&E — SES beams into receptive loan market — Ameropa grows bigger revolver — Acquisition hungry Better Collective ups bank line — Forth Ports docks into USPP market — CEE’s CTP consolidates debt in jumbo real estate financing
-
The City of London Corporation, via its endowment fund The City’s Cash, has launched first US private placements (PP), roadshowing the prospective notes this week and next. The funds will be partly used to finance the consolidation of the Billingsgate, Smithfield and Spitalfields wholesale food markets at a new site in Dagenham, Essex.
-
Luxembourg’s SES has refinanced its revolving credit facility, trimming at the margin of the €1.2bn deal as banks piled into the satellite operator’s transaction.
-
Buzzi Unicem has returned to the Schuldschein market, looking for at least €100m of debt in four maturities. The pricing levels are tighter than on the Italian cement and concrete group’s debut Schuldschein in 2017. Bankers thought this was thanks to investors' growing familiarity with the borrower, as well as a rating upgrade from Standard & Poor's.
